

BP-50632

Ivonescimab– Anti-PD-1/VEGF Bispecific Antibody

Ivonescimab (AK112) is a PD-1/VEGF bispecific antibody. Ivonescimab competitively inhibiting PD-1/PD-L1 interaction, reversing the immunosuppression mediated by it, and blocks the binding of VEGF-A to VEGFR2, inhibiting tumour angiogenesis in the tumour microenvironment. Ivonescimab also has significantly anticancer activity against EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer (NSCL).

Product Details	
Species Reactivity	Human
Source	Mammalian Cells
Isotype	Human IgG1 (L234A/L235A) kappa
Class	Anti-Human Bispecific antibodies
Type	Recombinant Humanized
Clone	SP34-2/OKT3
Target	Anti-human PD-1/VEGF
Purity	>99%
Molecular Weight	201.1 kDa
CAS Number	2428381-53-5
Formulation	NA
Storage conditions	Store at -80°C for 2 years. Aliquots should be stored at the same temperature after first use to avoid multiple freeze-thaws.